{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:26:42Z","timestamp":1761920802621},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Radiol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00256-020-03665-9","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T11:05:31Z","timestamp":1604919931000},"page":"1257-1262","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["BRAF inhibitor-induced panniculitis in patients treated for stage IV metastatic melanoma: a case series"],"prefix":"10.1007","volume":"50","author":[{"given":"David J.","family":"Bartlett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Erie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis I.","family":"Baffour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Broski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina N.","family":"Glazebrook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"issue":"10","key":"3665_CR1","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","volume":"28","author":"PB Chapman","year":"2017","unstructured":"Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol. 2017;28(10):2581\u20137.","journal-title":"Ann Oncol"},{"issue":"20","key":"3665_CR2","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dr\u00e9no B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867\u201376.","journal-title":"N Engl J Med"},{"issue":"9992","key":"3665_CR3","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444\u201351.","journal-title":"Lancet."},{"issue":"6892","key":"3665_CR4","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u201354.","journal-title":"Nature."},{"issue":"6","key":"3665_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/DAD.0000000000000023","volume":"36","author":"B Choy","year":"2014","unstructured":"Choy B, Chou S, Anforth R, Fern\u00e1ndez-Pe\u00f1as P. Panniculitis in patients treated with BRAF inhibitors: a case series. Am J Dermatopathol. 2014;36(6):493\u20137.","journal-title":"Am J Dermatopathol"},{"issue":"7","key":"3665_CR6","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/cup.12149","volume":"40","author":"GH Kim","year":"2013","unstructured":"Kim GH, Levy A, Compoginis G. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib. J Cutan Pathol. 2013;40(7):667\u20139.","journal-title":"J Cutan Pathol"},{"issue":"5","key":"3665_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/CMR.0b013e3283570792","volume":"22","author":"JB Monfort","year":"2012","unstructured":"Monfort JB, Pag\u00e8s C, Schneider P, Neyns B, Comte C, Bagot M, et al. Vemurafenib-induced neutrophilic panniculitis. Melanoma Res. 2012;22(5):399\u2013401.","journal-title":"Melanoma Res"},{"issue":"7","key":"3665_CR8","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1097\/DAD.0000000000000528","volume":"38","author":"I V\u00e1zquez-Osorio","year":"2016","unstructured":"V\u00e1zquez-Osorio I, S\u00e1nchez-Aguilar MD, Garc\u00eda-Rodi\u00f1o S, Su\u00e1rez-Pe\u00f1aranda JM, Aliste C, V\u00e1zquez-Veiga H. Vemurafenib-induced neutrophilic panniculitis: a new case and review of the literature. Am J Dermatopathol. 2016;38(7):e93\u20136.","journal-title":"Am J Dermatopathol"},{"issue":"3","key":"3665_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1001\/archdermatol.2011.2842","volume":"148","author":"L Zimmer","year":"2012","unstructured":"Zimmer L, Livingstone E, Hillen U, D\u00f6mkes S, Becker A, Schadendorf D. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol. 2012;148(3):357\u201361.","journal-title":"Arch Dermatol"},{"issue":"3","key":"3665_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2214\/AJR.12.9049","volume":"200","author":"RG Abramson","year":"2013","unstructured":"Abramson RG, Abramson VG, Chan E, Horn L, Keedy VL, Pao W, et al. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. AJR Am J Roentgenol. 2013;200(3):475\u201383.","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"3665_CR11","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1097\/RLU.0000000000001027","volume":"41","author":"SM Broski","year":"2016","unstructured":"Broski SM, Moran EK, Glazebrook KN, Nathan MA. BRAF inhibitor-induced panniculitis: appearance on 18F-FDG PET\/CT. Clin Nucl Med. 2016;41(3):e149\u201351.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"3665_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/RLU.0000000000001448","volume":"42","author":"I Mart\u00ednez-Rodr\u00edguez","year":"2017","unstructured":"Mart\u00ednez-Rodr\u00edguez I, Garc\u00eda-Casta\u00f1o A, Quirce R, Jim\u00e9nez-Bonilla J, Banzo I. Erythema nodosum-like panniculitis as a false-positive 18F-FDG PET\/CT in advanced melanoma treated with Dabrafenib and Trametinib. Clin Nucl Med. 2017;42(1):44\u20136.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"3665_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000461571","volume":"9","author":"M Negulescu","year":"2017","unstructured":"Negulescu M, Deilhes F, Sibaud V, Tournier E, Lamant L, Boulinguez S, et al. Panniculitis associated with MEK inhibitor therapy: an uncommon adverse effect. Case Rep Dermatol. 2017;9(1):80\u20135.","journal-title":"Case Rep Dermatol"},{"issue":"4","key":"3665_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","volume":"8","author":"RB Corcoran","year":"2018","unstructured":"Corcoran RB, Andr\u00e9 T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov. 2018;8(4):428\u201343.","journal-title":"Cancer Discov"},{"issue":"3","key":"3665_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/15384047.2018.1529113","volume":"20","author":"NA Richarz","year":"2019","unstructured":"Richarz NA, Puig L, P\u00e9rez N, Cuadra-Urteaga J, Elez E, Fern\u00e1ndez-Figueras MT. Vemurafenib-induced histiocytoid neutrophilic panniculitis simulating myeloid leukaemia cutis. Cancer Biol Ther. 2019;20(3):237\u20139.","journal-title":"Cancer Biol Ther"},{"issue":"7","key":"3665_CR16","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.21873\/anticanres.13549","volume":"39","author":"L Sollfrank","year":"2019","unstructured":"Sollfrank L, Lettmaier S, Erdmann M, Uslu U. Panniculitis under successful targeted inhibition of the MAPK\/ERK signaling pathway in a patient with BRAF V600E-mutated spindle cell oncocytoma of the pituitary gland. Anticancer Res. 2019;39(7):3955\u20139.","journal-title":"Anticancer Res"},{"issue":"9","key":"3665_CR17","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1111\/jdv.13039","volume":"29","author":"R M\u00f6ssner","year":"2015","unstructured":"M\u00f6ssner R, Zimmer L, Berking C, Hoeller C, Loquai C, Richtig E, et al. Erythema nodosum-like lesions during BRAF inhibitor therapy: report on 16 new cases and review of the literature. J Eur Acad Dermatol Venereol. 2015;29(9):1797\u2013806.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"3665_CR18","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2214\/AJR.09.2422","volume":"194","author":"O Catalano","year":"2010","unstructured":"Catalano O, Carac\u00f2 C, Mozzillo N, Siani A. Locoregional spread of cutaneous melanoma: sonography findings. AJR Am J Roentgenol. 2010;194(3):735\u201345.","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"3665_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1067\/j.cpradiol.2009.04.001","volume":"39","author":"O Catalano","year":"2010","unstructured":"Catalano O, Siani A. Cutaneous melanoma: role of ultrasound in the assessment of locoregional spread. Curr Probl Diagn Radiol. 2010;39(1):30\u20136.","journal-title":"Curr Probl Diagn Radiol"}],"container-title":["Skeletal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00256-020-03665-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00256-020-03665-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00256-020-03665-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T03:31:55Z","timestamp":1618025515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00256-020-03665-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["3665"],"URL":"https:\/\/doi.org\/10.1007\/s00256-020-03665-9","relation":{},"ISSN":["0364-2348","1432-2161"],"issn-type":[{"value":"0364-2348","type":"print"},{"value":"1432-2161","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,9]]},"assertion":[{"value":"29 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}